Key Takeaway: A patent owner’s unsuccessful eligibility argument does not necessarily make a case “exceptional” under 35 U.S.C. § 285. In a recent decision, the U.S. Court of Appeals for the Federal Circuit reversed a $9.1 million attorneys’ fee award, finding that the patent owner’s eligibility position required consideration beyond the Supreme Court’s decision in Association for Molecular Pathology v. Myriad Genetics, Inc.
In ChromaDex, Inc. v. Elysium Health, Inc., Case No. 25-1227 (Fed. Cir. Oct. 30, 2026), the Federal Circuit reversed the district court’s $9.1 million fee award, holding that the district court abused its discretion in finding the case “exceptional” under 35 U.S.C. § 285.
ChromaDex and the Trustees of Dartmouth College asserted patent claims directed to dietary supplement compositions containing isolated nicotinamide riboside (“NR”) and formulated for oral administration to increase nicotinamide adenine dinucleotide (“NAD+”) biosynthesis. NR occurs naturally in cow’s milk, although in trace amounts and in a form that is not bioavailable. ChromaDex argued that isolated NR possessed characteristics different from naturally occurring NR because isolated NR could increase NAD+ biosynthesis when orally administered.
The district court held the asserted claims patent-ineligible under 35 U.S.C. § 101 as directed to a product of nature, and the Federal Circuit affirmed in 2023. Following that decision, Elysium sought attorneys’ fees under § 285. The district court found the case exceptional, reasoning that the Supreme Court’s decision in Myriad specifically addressed the patent-eligibility issue presented and criticized ChromaDex for litigating as though Myriad did not exist. The district court subsequently awarded Elysium approximately $9.1 million in attorneys’ fees.
On appeal, the Federal Circuit reversed the fee award. Although the court did not alter its earlier determination that the claims were patent-ineligible, the court disagreed that Myriad resolved the eligibility question, stating that “the patent-eligibility question here required evaluating several considerations beyond Myriad.” In particular, the Federal Circuit explained that ChromaDex did not rely solely on the structural isolation of NR to establish patent eligibility. ChromaDex also relied on Natural Alternatives International, Inc. v. Creative Compounds, LLC to argue that isolated NR exhibited markedly different characteristics and significant utility because it could increase NAD+ biosynthesis in a way that naturally occurring NR in milk could not. Evaluating that position required consideration of several issues, including whether the claims required a particular quantity of NR, whether the claimed increase in NAD+ biosynthesis was attributable to NR, whether isolated NR was required to be bioavailable, and evidence that milk itself could increase NAD+ biosynthesis through a different pathway.
Although those arguments were ultimately insufficient to establish patent eligibility, the Federal Circuit determined that the eligibility analysis was not controlled by Myriad alone. The court therefore concluded that the district court had incorrectly assessed the substantive strength of ChromaDex’s § 101 position and abused its discretion in finding the case exceptional under § 285.
The Federal Circuit’s rationale highlights an important distinction between losing a patent-eligibility challenge and pursuing an exceptionally meritless position. For biotechnology patent owners asserting claims involving naturally occurring materials, the decision illustrates that eligibility may depend on more than whether a claimed substance occurs in nature, including whether the claimed composition demonstrates materially different characteristics or significant utility. While such arguments may ultimately fail to establish eligibility, their failure does not necessarily render the litigation exceptional for purposes of § 285.
Co-author: Amanda Eggart (Pending DC Bar Admission)
Editor: Brenden S. Gingrich, Ph.D.